Tag Archives: Baxter International

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Gilead Sciences (NASDAQ: GILD) and Genesis Healthcare (NYSE: GEN)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX – Research Report), Gilead Sciences (GILD – Research Report) and Genesis Healthcare (GEN – Research Report). Baxter International (BAX) In a report

Analysts Offer Insights on Healthcare Companies: Baxter International (NYSE: BAX), Agios Pharma (NASDAQ: AGIO) and Albireo Pharma (NASDAQ: ALBO)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Baxter International (BAX – Research Report), Agios Pharma (AGIO – Research Report) and Albireo Pharma (ALBO – Research Report) with bullish sentiments.

The SVP HR of Baxter International (NYSE: BAX) is Selling Shares

Today, the SVP HR of Baxter International (BAX – Research Report), Jeanne Mason, sold shares of BAX for $4.39M. In addition to Jeanne Mason, one other BAX executive reported Sell trades in the last month. See today’s analyst top recommended

Baxter International (BAX) Gets a Hold Rating from Barclays

Barclays analyst Kristen Stewart maintained a Hold rating on Baxter International (BAX – Research Report) yesterday and set a price target of $84.00. The company’s shares closed last Monday at $86.00. According to TipRanks.com, Stewart is a 3-star analyst with

Raymond James Reaffirms Their Buy Rating on Baxter International (BAX)

Raymond James analyst Lawrence Keusch maintained a Buy rating on Baxter International (BAX – Research Report) today and set a price target of $97.00. The company’s shares closed last Monday at $84.98. According to TipRanks.com, Keusch is a 4-star analyst

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX) and EyePoint Pharmaceuticals (NASDAQ: EYPT)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Baxter International (BAX – Research Report) and EyePoint Pharmaceuticals (EYPT – Research Report). Baxter International (BAX) Wells Fargo analyst Larry Biegelsen maintained a Buy rating